Study epoch | ||||||
---|---|---|---|---|---|---|
EDSS 3–6 | EDSS 4–6 | EDSS 6–6.5* | ||||
HR (95% CI) | p Value | HR (95% CI) | p Value | WAF (95% CI) | p Value | |
Sex (male) | 1.11 (0.86 to 1.43) | 0.42 | 1.33 (1.08 to 1.63) | 0.008 | 1.20 (1.04 to 1.37) | 0.01 |
Age at baseline (per year) | 1.01 (1.00 to 1.02) | 0.19 | 1.01 (1.00 to 1.02) | 0.07 | 0.99 (0.98 to 1.00) | 0.02 |
Disease duration at baseline (per year) | 0.99 (0.89 to 1.11) | 0.93 | 0.91 (0.83 to 1.00) | 0.05 | 0.96 (0.91 to 1.02) | 0.21 |
Annualised relapse rate | ||||||
Prebaseline (per relapse/year) | 0.92 (0.75 to 1.13) | 0.41 | 0.93 (0.76 to 1.13) | 0.44 | 0.79 (0.68 to 0.91) | 0.001 |
During epoch (per relapse/year) | 3.07 (2.56 to 3.70) | <0.001 | 2.41 (2.05 to 2.84) | <0.001 | 1.58 (1.45 to 1.73) | <0.001 |
Rate of prebaseline therapy initiation (per initiation/year) | 1.07 (0.60 to 1.91) | 0.81 | 1.10 (0.70 to 1.72) | 0.69 | 0.93 (0.69 to 1.24) | 0.60 |
Proportion of time on lower efficacy therapies | ||||||
Prebaseline (per 25% increase) | 1.01 (0.92 to 1.11) | 0.88 | 0.97 (0.90 to 1.05) | 0.51 | 1.04 (0.99 to 1.09) | 0.15 |
During epoch (per 25% increase) | 0.98 (0.90 to 1.07) | 0.61 | 1.00 (0.93 to 1.07) | 0.92 | 1.02 (0.97 to 1.06) | 0.49 |
Proportion of time on higher efficacy therapies | ||||||
Prebaseline (per 25% increase) | 0.74 (0.32 to 1.68) | 0.47 | 1.59 (1.22 to 2.07) | <0.001 | 1.10 (0.94 to 1.28) | 0.22 |
During epoch (per 25% increase) | 0.72 (0.59 to 0.89) | 0.002 | 0.79 (0.69 to 0.91) | <0.001 | 0.91 (0.84 to 0.99) | 0.02 |
Results of multivariable survival models for each epoch. Unless stated otherwise, Cox proportional hazard models were used.
*Weibull accelerated failure time model was used for this epoch.
EDSS, Expanded Disability Status Scale; WAF, Weibull acceleration factor.